Use of dihydroartemisinin in preparation of drug for inhibition of tumour growth

A technology of dihydroartemisinin and tumor, applied in the field of anti-tumor drugs, can solve the problems of lack of iron ion anti-tumor effect, aggravate cardiotoxicity, etc., and achieve the effects of obvious anti-cancer effect, less side effects of chemotherapy and safe medication

Inactive Publication Date: 2015-07-01
KUNSHAN DAREN BIOLOGICAL PHARMA CO LTD
View PDF3 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] 1. Cardiotoxicity: It can lead to severe myocardial injury and heart failure. The degree of myocardial injury is related to the dose, and the total amount is more than 500mg / m2.
Increased cardiotoxicity with radiation therapy or with mitomycin
[0012] 2. Dose-limiting toxicity: bone marrow suppression, leukopenia, thrombocytopenia and anemia, common granulocytopenia and lymphopenia
However, there is still a lack of systematic reports on the effect of iron ions on its anti-tumor effects in vivo and in vitro.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of dihydroartemisinin in preparation of drug for inhibition of tumour growth
  • Use of dihydroartemisinin in preparation of drug for inhibition of tumour growth
  • Use of dihydroartemisinin in preparation of drug for inhibition of tumour growth

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0230] Embodiment 1: Preparation of dihydroartemisinin tablet:

[0231] 1) Composition and dosage of raw and auxiliary materials:

[0232] Dihydroartemisinin 20g

[0233] Starch 55g

[0234] Lactose 55g

[0235] Sodium carboxymethyl starch 10g

[0236] Sodium Lauryl Sulfate 5g

[0237] Proper amount of povidone K30

[0238] Magnesium stearate 0.75g

[0239] Among them, dihydroartemisinin is a ready-made raw material purchased from a domestic pharmaceutical factory with GMP production qualification, and the quality standard of the raw material meets the international pharmacopoeia standard.

[0240] 2) Preparation process:

[0241] Dihydroartemisinin is passed through a 120 mesh sieve, and other auxiliary materials are passed through a 80 mesh sieve; Dihydroartemisinin is weighed according to the prescription amount, and starch, lactose, sodium carboxymethyl starch and sodium lauryl sulfate are mixed evenly; The 50% ethanol solution of % povidone K30 is a soft material ...

Embodiment 2

[0242] Embodiment 2: Preparation of dihydroartemisinin capsules:

[0243] 1) Composition and dosage of raw and auxiliary materials:

[0244] Dihydroartemisinin 20g

[0245] Starch 55g

[0246] Lactose 55g

[0247] Sodium carboxymethyl starch 10g

[0248] Sodium Lauryl Sulfate 5g

[0249] Proper amount of povidone K30

[0250] Magnesium stearate 0.75g

[0251] Among them, dihydroartemisinin is a ready-made raw material purchased from a domestic pharmaceutical factory with GMP production qualification, and the quality standard of the raw material meets the international pharmacopoeia standard.

[0252] 2) Preparation process:

[0253] Dihydroartemisinin is passed through a 120 mesh sieve, and other auxiliary materials are passed through a 80 mesh sieve; Dihydroartemisinin is weighed according to the prescription amount, and starch, lactose, sodium carboxymethyl starch and sodium lauryl sulfate are mixed evenly; The 50% ethanol solution of %povidone K30 is a soft material...

Embodiment 3

[0254] Embodiment 3: blank granule plus medicine mixing process:

[0255] Due to the poor thermal stability of dihydroartemisinin, during the preparation process, the heat generated by the frictional heat generation between the particles will also have an impact, so the present invention more preferably adopts the blank granule plus drug mixing process.

[0256] 1) Composition and dosage of raw and auxiliary materials:

[0257] Dihydroartemisinin 20g

[0258] Lactose 60g

[0259] Microcrystalline cellulose 60g

[0260] Sodium carboxymethyl starch 15g

[0261] Sodium Lauryl Sulfate 5g

[0262] Proper amount of povidone K30

[0263] Magnesium Stearate 0.5%

[0264] 2) Preparation process:

[0265] Dihydroartemisinin was pulverized at a low temperature below 20°C and passed through a 120-mesh sieve, and other excipients were passed through a 80-mesh sieve; lactose, microcrystalline cellulose, sodium carboxymethyl starch and sodium lauryl sulfate were weighed according to t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
hardnessaaaaaaaaaa
hardnessaaaaaaaaaa
Login to view more

Abstract

The invention discloses use of dihydroartemisinin in preparation of a drug for inhibition of tumour growth, and the tumour is liver cancer tumor, breast cancer tumor, melanoma or intestinal cancer tumor. The liver cancer tumor is human liver cancer HepG-2, human liver cancer QGY and human liver cancer SMMC. The breast cancer tumor is human breast cancer Bcap-37.The intestinal cancer tumor is human colon carcinoma Colo-205. The drug for inhibition of tumour growth may also include one of artemisinin and artemisinin derivative. The dihydroartemisinin can be used in preparation of the drug for inhibition of tumour growth, and is obvious in anti-cancer effect, small in side effect of chemotherapy, safe to use, and low in drug cost.

Description

technical field [0001] The invention relates to the technical field of antitumor drugs, in particular to the application of dihydroartemisinin in the preparation of drugs for inhibiting tumor growth. Background technique [0002] Tumor is a new organism formed by abnormal clonal proliferation caused by abnormal growth and proliferation of cells under the action of various carcinogenic factors. Tumors are generally divided into benign and malignant tumors, and the most common malignant tumor is commonly referred to as cancer. Tumor is a disease caused by mutation or damage of related genes, abnormal or disordered gene expression. The function, structure and metabolism of tumor cells are different from normal cells, and its biological characteristics are mainly uncontrolled cell proliferation and ability to invade surrounding tissues. Ability to metastasize distantly through the internal circulatory system or lymphatic system, and can stably inherit its malignant characterist...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/357A61K33/26A61K31/44A61K33/24A61K31/675A61K31/704A61P35/00A61P35/04
Inventor 任克勇罗旭华戴俊东尹蓓珮李炳生
Owner KUNSHAN DAREN BIOLOGICAL PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap